Now live: Pro — the full 13F research suite for serious investorsSee pricing →
22NW, LP

Q2 2024 · 13F-HR

22NW, LPholdings as filed

Filed 2024-08-14 · accession 0001214659-24-014708

$117.2M
Reported value
13
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
350060109FSTRFOSTER L B CO$28.3M24.1%1,313,121CommonSOLE
514766104LFCRLIFECORE BIOMEDICAL INC$24.0M20.5%1,755,161CommonSOLE
034569103ANEBANEBULO PHARMACEUTICALS INC$14.6M12.5%5,366,290CommonSOLE
859241101STRLSTERLING INFRASTRUCTURE INC$11.8M10.1%99,783CommonSOLE
068463108BBSIBARRETT BUSINESS SVCS INC$8.7M7.41%264,904CommonSOLE
230215105CULPCULP INC$5.5M4.73%1,236,789CommonSOLE
71742W103PFXPHENIXFIN CORP$5.5M4.70%117,885CommonSOLE
307675108FB1FARMER BROS CO$5.2M4.47%1,955,526CommonSOLE
23331S100DHXDHI GROUP INC$4.3M3.69%2,068,490CommonSOLE
563571405MTWMANITOWOC CO INC$4.1M3.50%356,115CommonSOLE
516544103LNTHLANTHEUS HLDGS INC$2.8M2.37%34,562CommonSOLE
86272A305SSKNSTRATA SKIN SCIENCES INC$1.6M1.41%536,995CommonSOLE
744375205PMDUSDPSYCHEMEDICS CORP$664,0920.57%274,418CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.